By Denny Jacob

Alcon reported topline results from two trials evaluating AR-15512, a candidate treatment for dry-eye disease.

The eye-care company said the primary endpoint achieved statistical significance in both trials. Additional data derived from secondary endpoints demonstrated the rapid onset and sustained tear production, said Alcon.

AR-15512 was well tolerated and no serious ocular adverse events were reported.

Alcon expects to file a new drug application for AR-15512 with the U.S. Food and Drug Administration in mid-2024.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

January 09, 2024 17:05 ET (22:05 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Alcon (NYSE:ALC)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Alcon
Alcon (NYSE:ALC)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Alcon